CryoLife, FDA Extend Interim Operating Agreement To March 20
This article was originally published in The Gray Sheet
Executive Summary
CryoLife anticipates filing an investigational device exemption submission with FDA to expand the indication of BioGlue for the sealing of dura mater by late 2003